Functionalised Chitosan Galectin-3 Modulation for Respiratory Fibrosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for respiratory and hepatic pathologies characterized by inflammation and fibrosis, particularly those caused by viral infections, lack effective modulation of galectins and often have significant side effects.
Innovation Solution
The use of functionalized chitosan or its salts, which inhibit galectin-3 activity, thereby reducing the inflammatory cascade and fibrosis in respiratory and hepatic tissues, and are combined with pharmacologically active substances or biological function substances to enhance therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for inflammatory and fibrotic pathologies, then some therapeutic effect is achieved, but significant side effects occur and galectin modulation is ineffective
Solution Approach 1:
The patent uses functionalized chitosan as an intermediary substance that specifically targets and modulates galectin-3 activity. This mediator approach allows therapeutic intervention in the inflammatory cascade without directly suppressing all immune responses, thereby achieving efficacy while reducing harmful side effects compared to conventional broad-spectrum anti-inflammatory treatments.
Solution Approach 2:
The invention modifies the chemical structure of chitosan through functionalization to create specific molecular configurations that can bind to and modulate galectin-3. By changing the chemical parameters of the treatment substance, the patent achieves selective galectin modulation with improved therapeutic profile and reduced side effects compared to conventional treatments.
2Ease of operation
If galectin regulation is not targeted specifically, then conventional treatments can be used, but the inflammatory cascade remains dysregulated and fibrosis progresses
Solution Approach 1:
Functionalized chitosan serves as a specific intermediary that targets galectin-3, the key regulator of the inflammatory cascade. This targeted approach ensures reliable inflammation control by addressing the specific molecular mechanism driving fibrosis, while the administration remains as simple as conventional treatments.
3Ease of manufacture
If viral infections are not addressed, then treatment can focus only on symptoms, but the underlying cause of inflammation and fibrosis persists
Solution Approach 1:
The functionalized chitosan acts as an intermediary that addresses both the viral infection impact and the subsequent inflammatory cascade by modulating galectin-3. This dual-action approach controls disease progression more reliably than symptom-only treatment, while maintaining comparable treatment complexity through a single therapeutic agent.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The functionalized chitosan composition effectively reduces inflammation and fibrosis by inhibiting galectin-3, offering a potential treatment for viral-induced pathologies with minimized side effects, as demonstrated by reduced viral replication and improved tissue function markers.
Implementation Method 1
functionalised chitosan, or a salt thereof, is able to act as a modulator of galectins, in particular galectin-3
Data Source
AI summary
The invention discloses a functionalised chitosan, or a salt thereof, used in the treatment of pathologies of the respiratory tract or hepatic pathologies, preferably caused by viral infections. It was indeed observed that said functionalised chitosan or salt thereof was able to act as galectin-modulator, modulating in particular galectin-3, and therefore determining a marked reduction in the inflammatory and fibrotic cascade generated by these viral infections. The invention moreover discloses a pharmaceutical composition, as well as a biomaterial, comprising this functionalised chitosan, or a salt thereof.